Comprehensive Monograph on Indacaterol (DB05039)

Executive Summary

Indacaterol is a small molecule pharmaceutical agent classified as a selective, ultra-long-acting beta-2 adrenergic agonist (ultra-LABA). Developed by Novartis, it is indicated for the long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and emphysema.[1] Its mechanism of action involves high-efficacy agonism at the β2-adrenoceptors located on airway smooth muscle, which stimulates adenylyl cyclase, increases intracellular cyclic adenosine monophosphate (cAMP), and results in potent bronchodilation.[1]

Pharmacologically, Indacaterol is distinguished by a unique profile that combines a rapid onset of action, observed within five minutes of inhalation, with a sustained 24-hour duration of effect.[1] This dual characteristic, which permits effective once-daily dosing, is attributed to its high intrinsic agonist activity and its high affinity for lipid raft microdomains in the cell membrane, creating a local depot for sustained receptor activation.[1]

The clinical development program for Indacaterol has robustly demonstrated its efficacy in improving lung function, as measured by trough forced expiratory volume in one second (FEV1​), and enhancing patient-reported outcomes, including dyspnea and health-related quality of life, in individuals with moderate to severe COPD.[5] Head-to-head comparative trials and network meta-analyses have consistently shown Indacaterol to be superior to placebo and established twice-daily LABAs such as salmeterol and formoterol.[5]

The safety profile of Indacaterol is well-characterized and generally comparable to other agents in its class.[5] The most common adverse events include nasopharyngitis and a distinctive, transient post-inhalation cough that is typically mild and not associated with bronchospasm.[1] As a LABA, Indacaterol carries a class-wide U.S. Food and Drug Administration (FDA) Boxed Warning regarding the increased risk of asthma-related death and is contraindicated for the treatment of asthma as monotherapy.[10] Other significant warnings include the potential for cardiovascular effects, hypokalemia, and paradoxical bronchospasm.[10]

Indacaterol received regulatory approval from the European Medicines Agency (EMA) as Onbrez Breezhaler and from the FDA as Arcapta Neohaler.[1] While its use as a monotherapy has been discontinued in the United States market, it remains a cornerstone component of modern, guideline-recommended dual (LAMA/LABA) and triple (LAMA/LABA/ICS) combination therapies for COPD.[13] This positions Indacaterol as a pivotal molecule that has advanced COPD management by offering a unique combination of rapid and sustained bronchodilation.

Chemical Identity and Physicochemical Properties

Structural Description and Nomenclature

Indacaterol is a synthetic small molecule belonging to the monohydroxyquinoline class of organic compounds.[12] Its complex chemical architecture is precisely defined by its International Union of Pure and Applied Chemistry (IUPAC) name: 5--1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one.[12]

The structure is composed of two primary moieties:

1. A hydrophilic "head" group: An 8-hydroxyquinolin-2-one core, which is a derivative of quinoline. This part of the molecule contains the ethanolamine side chain responsible for interacting with the β2-adrenergic receptor.
2. A lipophilic "tail" group: A 5,6-diethyl-indan group, which contributes significantly to the molecule's lipophilicity and is crucial for its unique pharmacokinetic and pharmacodynamic properties.[12]

Functionally, it is classified as a quinolone, a member of indanes, a secondary alcohol, and a secondary amino compound.[12]

!(https://upload.wikimedia.org/wikipedia/commons/thumb/c/c8/Indacaterol\_structure.svg/512px\-Indacaterol\_structure.svg.png)

Figure 1: Skeletal formula of Indacaterol.20

Stereochemistry and Chirality

Indacaterol is a chiral molecule, containing a single stereocenter at the carbon atom bearing the hydroxyl group within the ethanolamine side chain.[1] The therapeutic product is formulated exclusively as the pure (R)-enantiomer, as specified by the (1R) designation in its IUPAC name.[1]

The decision to develop a single enantiomer rather than a racemic mixture is a critical aspect of its design. In chiral pharmacology, it is common for one enantiomer (the eutomer) to possess the majority of the desired therapeutic activity, while the other enantiomer (the distomer) may be inactive, less active, or contribute to off-target effects and adverse reactions. The selection of the pure (R)-enantiomer for clinical use implies that extensive preclinical evaluation identified this specific stereoisomer as having the optimal balance of high-potency agonist activity at the β2-receptor and minimal activity at other receptors, such as the β1-receptor, which is abundant in cardiac tissue. This stereochemical purity is a key quality attribute of the drug substance and is fundamental to achieving its favorable efficacy and selectivity profile.[2]

Salt Form and Physical Properties

For clinical use and formulation stability, Indacaterol is prepared as a maleate salt: Indacaterol maleate.[1] This salt form has a distinct CAS number (753498-25-8) and molecular formula (

C28​H32​N2​O7​) from the free base.[21] Physically, it is described as an off-white to light yellow crystalline solid.[17]

Regarding its solubility, Indacaterol exhibits properties typical of a lipophilic compound intended for inhalation. It is soluble in organic solvents like dimethyl sulfoxide (DMSO) and dimethylformamide (DMF), has limited solubility in ethanol, and is not soluble in water.[17] This low aqueous solubility is advantageous for an inhaled drug, as it promotes retention within the lung tissue, contributing to its long duration of action.

For stability, long-term storage is recommended at -20°C, with short-term storage at 2-8°C under an inert atmosphere, protected from moisture and light.[17] The formulated capsules are particularly sensitive to moisture and must be stored in their original blister packaging and removed only immediately before use with the inhaler device.[11]

Table 1: Chemical and Physical Properties of Indacaterol

Property	Details	Source(s)
Drug Name	Indacaterol	12
DrugBank ID	DB05039	1
Type	Small Molecule	1
IUPAC Name	5--1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one	12
Molecular Formula	Free Base: C24​H28​N2​O3​ Maleate Salt: C28​H32​N2​O7​	12
Molecular Weight	Free Base: 392.50 g/mol Maleate Salt: 508.57 g/mol	17
CAS Number	Free Base: 312753-06-3 Maleate Salt: 753498-25-8	12
Other Identifiers	InChIKey: QZZUEBNBZAPZLX-QFIPXVFZSA-N SMILES: CCC1=C(C=C2CC(CC2=C1)NCC@@HO)CC ChEBI ID: CHEBI:68575 ChEMBL ID: CHEMBL1095777 UNII: 8OR09251MQ
Synonyms	QAB149, QAB-149, Indacterol
Physical Appearance	Off-white to light yellow solid; Crystalline solid
Solubility	Soluble in DMSO, DMF; sparingly soluble in ethanol; insoluble in water
Storage Conditions	2-8°C (short-term) or -20°C (long-term), under inert atmosphere, protected from moisture and light

Pharmacology

Pharmacodynamics and Mechanism of Action

Indacaterol exerts its therapeutic effect as a potent, selective beta-2 adrenergic receptor agonist. When administered via inhalation, it acts locally within the lungs to produce bronchodilation. The primary molecular target is the β2-adrenergic receptor, a G-protein coupled receptor predominantly expressed on the surface of airway smooth muscle cells.

The binding of Indacaterol to the β2-receptor initiates a well-defined intracellular signaling cascade. This activation stimulates the enzyme adenylyl cyclase, which catalyzes the conversion of adenosine triphosphate (ATP) to the second messenger cyclic-3',5'-adenosine monophosphate (cAMP). The resultant increase in intracellular cAMP levels leads to the activation of protein kinase A, which in turn phosphorylates various target proteins. This cascade culminates in the relaxation of bronchial smooth muscle, leading to an increase in the diameter of the airways and alleviating airflow obstruction. Additionally, elevated cAMP levels can inhibit the release of inflammatory mediators of immediate hypersensitivity from cells, particularly mast cells.

A key feature of Indacaterol is its high receptor selectivity. In vitro studies have quantified this selectivity, showing that Indacaterol possesses more than 24-fold greater agonist activity at β2-receptors compared to β1-receptors and 20-fold greater agonist activity compared to β3-receptors. This selectivity profile, which is comparable to that of formoterol, is clinically significant. While β2-receptors are predominant in the airways, β1-receptors are predominant in the heart. The high selectivity of Indacaterol for the β2-receptor is presumed to minimize off-target cardiac stimulation, contributing to its favorable cardiovascular safety profile.

Indacaterol is distinguished within its class as an "ultra-long-acting" β2-agonist (ultra-LABA), a designation stemming from its unique combination of a rapid onset and a 24-hour duration of action. This dual-action profile is a direct consequence of its molecular structure and interactions within the cellular microenvironment.

• Rapid Onset of Action: The rapid onset, with bronchodilation occurring within five minutes of inhalation, is attributed to its high intrinsic efficacy. Indacaterol acts as a high-efficacy, or near-full, agonist at the β2-receptor, with a maximal effect ( Emax​) of 73% relative to the full agonist isoprenaline, which is substantially higher than that of the partial agonist salmeterol (38%). This high efficacy allows the drug to efficiently and rapidly activate the receptor population, triggering a swift physiological response.
• Ultra-Long Duration of Action: The 24-hour duration of action is governed by a different property: its high lipophilicity, conferred by the indane "tail" of the molecule. This property facilitates a high affinity for lipid raft microdomains within the plasma membrane of airway cells. The molecule effectively partitions into these lipid-rich areas, forming a local "depot" within the lung tissue. From this depot, Indacaterol slowly dissociates over time to continuously re-engage with and stimulate the β2-receptors. This slow-release mechanism from the membrane microenvironment, rather than a slow dissociation from the receptor itself, is the key to its prolonged therapeutic effect and allows for the convenience of once-daily administration.

This combination of a fast-acting head group and a long-acting tail group within a single molecule represents a significant pharmacological advancement, providing patients with both immediate symptom relief and sustained, 24-hour airway patency.

Pharmacokinetics

The pharmacokinetic profile of Indacaterol has been extensively studied, revealing characteristics consistent with its intended use as a once-daily inhaled therapy for local action in the lungs, but with notable systemic exposure.

Absorption: Following oral inhalation, Indacaterol is absorbed rapidly, with the median time to reach peak serum concentrations (Tmax) occurring at approximately 15 minutes after single or repeated doses. For an inhaled drug, it demonstrates substantial systemic exposure, with an average absolute bioavailability of 43% to 45%.

Distribution: The drug exhibits extensive distribution throughout the body, as indicated by a very large volume of distribution (Vz​) ranging from 2,361 to 2,557 liters following intravenous infusion. This suggests significant partitioning into tissues outside the plasma compartment. In human plasma and serum, Indacaterol is highly bound to proteins, with binding percentages ranging from 94.1% to 96.2%.

Metabolism: Indacaterol undergoes extensive metabolism. Following oral administration of a radiolabeled dose, unchanged Indacaterol was the main component in serum, accounting for about one-third of the total drug-related area under the curve (AUC) over 24 hours. The primary metabolic pathways are hydroxylation and direct glucuronidation.

In vitro studies have identified the key enzymes involved: UDP-glucuronosyltransferase 1A1 (UGT1A1) is the sole isoform responsible for metabolizing Indacaterol to its phenolic O-glucuronide, while Cytochrome P450 3A4 (CYP3A4) is the predominant isoenzyme responsible for its hydroxylation. Other CYP isoenzymes, including CYP1A1 and CYP2D6, also play a minor role in hydroxylation.

Excretion: Elimination of Indacaterol and its metabolites occurs primarily through the fecal route. In a human mass balance study using an oral dose, 54% of the dose was excreted in the feces as the unchanged parent drug, and an additional 23% was excreted as hydroxylated metabolites. Renal clearance plays a very minor role in the elimination of systemically available drug, accounting for only 2% to 6% of the total systemic clearance. The total serum clearance of Indacaterol is in the range of 18.8 to 23.3 L/h.

Half-Life and Steady State: The decline of Indacaterol serum concentrations is multi-phasic, characterized by a very long average terminal half-life ranging from 45.5 to 126 hours. However, the

effective half-life, which is more clinically relevant for determining dosing intervals and accumulation, is calculated to be between 40 and 56 hours based on accumulation after repeated once-daily dosing. This effective half-life is consistent with the observed time to reach steady-state plasma concentrations, which is approximately 12 to 15 days of once-daily administration.

Table 2: Pharmacokinetic Parameters of Inhaled Indacaterol

Parameter	Value	Source(s)
Time to Peak Concentration (Tmax)	~15 minutes
Absolute Bioavailability	43% - 45%
Volume of Distribution (Vz​)	2,361 - 2,557 L
Plasma Protein Binding	94.1% - 96.2%
Terminal Half-life	45.5 - 126 hours
Effective Half-life (from accumulation)	40 - 56 hours
Time to Steady State	~12 - 15 days
Serum Clearance	18.8 - 23.3 L/h
Primary Route of Elimination	Fecal (54% as unchanged drug, 23% as metabolites)
Key Metabolizing Enzymes	UGT1A1, CYP3A4

Clinical Development and Efficacy in COPD

Overview of Clinical Trial Program

Indacaterol has been subjected to a comprehensive and robust clinical development program, encompassing numerous Phase II, III, and IV trials. The primary focus of this program has been to establish its efficacy and safety for the maintenance treatment of patients with moderate-to-severe COPD. These trials have rigorously evaluated Indacaterol as both a monotherapy and as a component of fixed-dose combination therapies. The comparator arms in these studies have included placebo as well as established active treatments, such as the long-acting anticholinergic (LAMA) tiotropium and the twice-daily LABAs salmeterol and formoterol. The consistent endpoints assessed across this extensive program provide a clear picture of its clinical utility, focusing on objective measures of lung function (trough

FEV1​), patient-reported outcomes of breathlessness (Transition Dyspnea Index, TDI) and health status (St. George's Respiratory Questionnaire, SGRQ), and rates of disease exacerbation.

Efficacy as Monotherapy

The efficacy of Indacaterol as a once-daily monotherapy has been firmly established in several large-scale, long-term clinical trials.

Lung Function (FEV1​):

Pivotal trials have consistently demonstrated that Indacaterol, at doses of 150 µg and 300 µg, provides statistically significant and clinically meaningful improvements in trough FEV1​ (the primary measure of 24-hour bronchodilator effect) compared to placebo. For instance, the 6-month INLIGHT-2 study found that Indacaterol 150 µg increased trough

FEV1​ by a substantial 170 mL more than placebo at week 12 (p<0.001). This level of improvement exceeds the commonly accepted minimum clinically important difference (MCID) of 100-140 mL.

In head-to-head comparisons, Indacaterol has shown superior efficacy to older, twice-daily LABAs. The INLIGHT-2 study also reported that Indacaterol 150 µg once daily provided a 60 mL greater improvement in trough FEV1​ compared to salmeterol 50 µg twice daily (p<0.001). Similarly, other studies and meta-analyses have confirmed its superiority over formoterol. When compared to the once-daily LAMA tiotropium, Indacaterol has demonstrated non-inferior or similar efficacy in improving

FEV1​.

Patient-Reported Outcomes:

The benefits of Indacaterol extend beyond objective lung function measurements to significant improvements in patients' daily lives.

• Health Status (SGRQ): Treatment with Indacaterol leads to clinically important reductions in the SGRQ total score, a comprehensive measure of health-related quality of life in respiratory disease. In the INLIGHT-2 trial, the improvement with Indacaterol versus placebo at 12 weeks was -6.3 points, exceeding the MCID of -4 points. Furthermore, a significantly greater proportion of patients treated with Indacaterol achieved this MCID compared to both placebo and salmeterol.
• Dyspnea (TDI): Indacaterol provides significant relief from dyspnea (breathlessness), a primary and debilitating symptom of COPD. Studies consistently show that Indacaterol treatment results in a clinically meaningful improvement in the TDI focal score compared to placebo, with effects that are often numerically and sometimes statistically superior to those of salmeterol.

Symptom Control and Rescue Medication Use:

Consistent with its potent, 24-hour bronchodilator effect, treatment with Indacaterol leads to better overall symptom control. This is evidenced by a significant reduction in the need for as-needed short-acting beta-agonist (SABA) rescue medication and a corresponding increase in the percentage of days where patients require no rescue medication at all, compared to both placebo and salmeterol.

Efficacy in Combination Therapies

The therapeutic role of Indacaterol has evolved, and it is now a foundational component of leading combination inhalers, aligning with global treatment strategies that recommend dual bronchodilation for many symptomatic COPD patients.

• Dual Bronchodilation (LAMA/LABA): Indacaterol is a key ingredient in several highly effective fixed-dose combinations with the LAMA glycopyrronium (marketed as Ultibro Breezhaler or Utibron Neohaler). Extensive clinical trials have demonstrated that these LAMA/LABA combinations provide superior bronchodilation, greater symptom relief, and improved health status compared to their individual monocomponents (Indacaterol or glycopyrronium alone) and other monotherapies like tiotropium.
• Triple Therapy (LAMA/LABA/ICS): For patients with more severe disease, a history of frequent exacerbations, and/or evidence of eosinophilic inflammation, Indacaterol is also formulated in once-daily single-inhaler triple therapies. These products combine Indacaterol with a LAMA (glycopyrronium) and an inhaled corticosteroid (ICS) such as mometasone furoate (Enerzair Breezhaler) or budesonide. This approach aligns with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy for escalating treatment in high-risk patients.

Table 3: Summary of Key Phase III Clinical Trials for Indacaterol Monotherapy in COPD

Trial Name/Identifier	Duration	Patient Population	Treatment Arms	Primary Endpoint	Key Results vs. Placebo (Trough FEV1​ at Week 12)	Key Results vs. Active Comparator (Trough FEV1​ at Week 12)	Source(s)
INLIGHT-2 (NCT00624286)	26 weeks	Moderate-to-severe COPD	Indacaterol 150 µg OD; Salmeterol 50 µg BID; Placebo	Trough FEV1​ at Week 12	+170 mL (p<0.001)	Superior to Salmeterol by +60 mL (p<0.001)
INVOLVE (NCT00393458)	52 weeks	Moderate-to-severe COPD	Indacaterol 300 µg OD; Formoterol 12 µg BID; Placebo	Trough FEV1​ at Week 12	+170 mL (p<0.001)	Superior to Formoterol by +50 mL (p<0.001)
INHANCE (NCT00622635)	26 weeks	Moderate-to-severe COPD	Indacaterol 150 µg OD; Indacaterol 300 µg OD; Placebo	Trough FEV1​ at Week 12	150 µg: +180 mL (p<0.001) 300 µg: +180 mL (p<0.001)	N/A
INTENSITY (NCT00900731)	12 weeks	Moderate-to-severe COPD	Indacaterol 150 µg OD; Tiotropium 18 µg OD	Trough FEV1​ at Week 12	N/A (no placebo arm)	Non-inferior to Tiotropium (difference of -10 mL)
INTRUST-1 & 2 (NCT00876694, NCT00877383)	12 weeks	Severe COPD (on tiotropium)	Indacaterol 150 µg OD + Tiotropium; Placebo + Tiotropium	Trough FEV1​ at Week 12	+130 mL (p<0.001)	N/A

OD = once daily; BID = twice daily

Comparative Analysis within the LABA Class

The introduction of Indacaterol prompted a re-evaluation of the therapeutic landscape for LABAs in COPD. Its performance has been extensively compared against both older, twice-daily agents and newer, once-daily ultra-LABAs.

vs. Twice-Daily LABAs (Salmeterol, Formoterol)

Direct head-to-head clinical trials have established a clear efficacy advantage for Indacaterol over the conventional twice-daily LABAs, salmeterol and formoterol.

• Efficacy: As highlighted in pivotal trials like INLIGHT-2 and INVOLVE, Indacaterol (at 150 µg and 300 µg doses) consistently provides statistically superior 24-hour bronchodilation, measured by trough FEV1​, compared to standard doses of salmeterol 50 µg BID and formoterol 12 µg BID. This superior lung function improvement is often accompanied by greater benefits in patient-reported outcomes, such as health status (SGRQ) and dyspnea (TDI), when compared to salmeterol.
• Onset and Duration: A key differentiator is the combination of rapid onset and extended duration. Indacaterol's onset of action within 5 minutes is comparable to the fast-acting formoterol and significantly quicker than salmeterol. This rapid effect is paired with a true 24-hour duration of action, which underpins its once-daily (OD) dosing regimen. This contrasts with the 12-hour duration of salmeterol and formoterol, which necessitates a twice-daily (BID) schedule. The convenience of once-daily administration is widely considered to be a significant factor in improving long-term patient adherence to maintenance therapy.
• Safety: The overall safety and tolerability profiles of Indacaterol are largely comparable to those of salmeterol and formoterol, with similar rates of cardiovascular and other systemic adverse events observed in comparative trials.

vs. Once-Daily Ultra-LABAs (Olodaterol, Vilanterol)

Direct, head-to-head trials comparing the once-daily ultra-LABAs are scarce. Therefore, the relative positioning of Indacaterol against olodaterol and vilanterol is primarily informed by evidence from network meta-analyses (NMAs), which allow for indirect comparisons across different trials.

• Efficacy Findings from NMAs: Multiple comprehensive NMAs, synthesizing data from dozens of randomized controlled trials, have consistently positioned Indacaterol as one of the most, if not the most, effective LABA monotherapies for COPD.
• In terms of improving trough FEV1​, Indacaterol at doses of 150 µg and 300 µg was associated with statistically significant improvements compared to all other LABA monotherapies, including olodaterol (5 µg and 10 µg) and vilanterol (25 µg), at both 12 and 24 weeks.
• For patient-reported outcomes, Indacaterol 300 µg demonstrated a significant improvement in the TDI focal score (dyspnea) compared to all other LABAs.
• Regarding exacerbation prevention, Indacaterol 150 µg showed significantly better results in reducing exacerbation rates compared to both doses of olodaterol.
• Interpretation and Methodological Considerations: While these NMA results suggest a superior efficacy profile for Indacaterol, a nuanced, expert interpretation requires acknowledging the inherent limitations of indirect comparisons. The validity of an NMA rests on the assumption that the trials being compared are sufficiently similar (homogeneous) in their design and patient populations. Critiques of these comparisons have highlighted potentially significant sources of heterogeneity that could confound the results. For example, a key analysis comparing olodaterol and Indacaterol noted that the pivotal olodaterol trials included patients with a broader range of disease severity (GOLD stages II–IV) and, crucially, permitted the use of concomitant maintenance bronchodilators like tiotropium. In contrast, the pivotal Indacaterol trials were generally restricted to patients with moderate-to-severe COPD (GOLD stages II/III) and disallowed concomitant long-acting bronchodilators. This difference is a major potential confounder; the olodaterol trial population may have been more severe and already receiving background therapy, which could blunt the apparent treatment effect of olodaterol relative to the effect of Indacaterol observed in a less confounded population. Therefore, while the NMA evidence consistently favors Indacaterol, this conclusion must be tempered by the understanding that it is based on indirect evidence from heterogeneous trials.

Table 4: Comparative Efficacy of LABA Monotherapies in COPD (Summary of NMA Findings)

Endpoint	Efficacy Ranking / Key Comparison	Source(s)
Trough FEV1​ (at 12 and 24 weeks)	1. Indacaterol 300 µg OD 2. Indacaterol 150 µg OD Both were statistically superior to all other LABA monotherapies (Indacaterol 75 µg, Vilanterol 25 µg, Salmeterol 50 µg, Olodaterol 10/5 µg, Formoterol 12 µg).
Transition Dyspnea Index (TDI) (at 12 or 24 weeks)	Indacaterol 300 µg OD was associated with statistically significant improvement compared to all other LABAs.
St. George's Respiratory Questionnaire (SGRQ)	Indacaterol (150/300 µg) was dominant in SGRQ score improvement in an earlier NMA. Later analyses showed no statistically significant differences among many agents.
Rate of COPD Exacerbations	Indacaterol 150 µg OD had significantly lower exacerbation rates than Olodaterol 5 µg and 10 µg OD.

OD = once daily; BID = twice daily. Rankings are based on the point estimates of effect from Bayesian network meta-analyses.

Safety, Tolerability, and Risk Management

The safety profile of Indacaterol is well-established through its extensive clinical trial program and post-marketing surveillance. It is generally well-tolerated, with a risk profile consistent with the β2-adrenergic agonist class.

Adverse Event Profile

The most commonly reported adverse drug reactions are typically mild to moderate in severity and tend to decrease in frequency with continued treatment.

• Common Adverse Events: At the recommended therapeutic doses, the most frequent adverse events include nasopharyngitis (inflammation of the nose and pharynx), upper respiratory tract infections, headache, and cough. Other common events reported in clinical trials include muscle spasms, peripheral edema, and musculoskeletal pain.
• Post-Inhalation Cough: A characteristic and frequently noted adverse event is a transient, non-productive cough that occurs within 15 seconds of inhalation. This cough is typically mild, lasts for only a few seconds, and is not associated with subsequent bronchospasm or a loss of efficacy. Importantly, it has rarely led to treatment discontinuation in clinical trials.
• Serious Adverse Events (SAEs): The overall incidence of SAEs in patients treated with Indacaterol is similar to that observed with placebo and other active comparators like salmeterol. The most common SAEs fall into the categories of respiratory events, such as COPD worsening (exacerbation), and infections.

Table 5: Summary of Common and Serious Adverse Events

Adverse Event Category	Specific Events	Frequency	Source(s)
Very Common (>10%)	Upper respiratory tract infection	Very Common
Common (1-10%)	Nasopharyngitis, Cough, Headache, Muscle Spasm, Dizziness, Peripheral Edema, Musculoskeletal pain, Diabetes mellitus and hyperglycemia, Ischemic heart disease, Dyspepsia	Common
Uncommon (0.1-1%)	Hypersensitivity, Insomnia, Glaucoma, Pruritus/Rash	Uncommon
Class Effect Events	Tachycardia, Tremor, Palpitations	Rarely reported
Serious Events of Note	Paradoxical Bronchospasm, Angioedema	Rare but serious

Warnings and Precautions

Indacaterol use is associated with several important warnings and precautions, many of which are class effects for LABAs.

• FDA Boxed Warning: Asthma-Related Death: All products containing a LABA, including Indacaterol, carry a boxed warning from the U.S. FDA. This warning is based on data from a large study with another LABA (salmeterol) that showed an increase in asthma-related deaths in patients receiving the drug. Consequently, LABAs are contraindicated for the treatment of asthma without the concomitant use of a long-term asthma control medication, such as an inhaled corticosteroid. Indacaterol is not indicated for the treatment of asthma.
• Deterioration of Disease and Acute Episodes: Indacaterol is a maintenance bronchodilator and should not be initiated in patients with acutely deteriorating COPD or for the treatment of acute bronchospasm (i.e., as a rescue therapy). Patients should be prescribed a short-acting bronchodilator for acute symptoms.
• Cardiovascular Effects: As a sympathomimetic amine, Indacaterol can produce clinically significant cardiovascular effects in some patients, including increases in pulse rate and blood pressure, and has the potential to prolong the QTc interval. It should be used with caution in patients with known cardiovascular disorders such as coronary artery disease, cardiac arrhythmias, and hypertension.
• Paradoxical Bronchospasm: As with other inhaled medications, Indacaterol can cause paradoxical bronchospasm, a potentially life-threatening event where the airways constrict immediately after inhalation. If this occurs, treatment should be discontinued immediately and alternative therapy instituted.
• Hypokalemia and Hyperglycemia: Beta-2 agonists have the potential to produce significant hypokalemia (low serum potassium) in some patients, which can lead to adverse cardiovascular effects. They may also cause transient hyperglycemia (high blood sugar). Caution is warranted in patients with pre-existing hypokalemia and in those with diabetes mellitus.
• Hypersensitivity Reactions: Immediate hypersensitivity reactions, including angioedema, urticaria, and rash, have been reported. The formulation contains lactose, which may contain milk proteins, so it should be used with caution in patients with a severe milk protein allergy.

Contraindications and Interactions

• Contraindications: Indacaterol is contraindicated in patients with asthma as monotherapy and in patients with a known hypersensitivity to Indacaterol or any of the excipients (including milk protein).
• Drug-Food/Alcohol Interactions:
• Food: There are no specific food interactions reported, but the presence of lactose as an excipient means patients with a severe milk protein allergy should use it with caution.
• Alcohol: There are no well-defined pharmacokinetic interactions with alcohol. However, some sources advise avoiding or limiting alcohol consumption as it may worsen potential side effects like dizziness. Clinical trial protocols often include restrictions on alcohol use around the time of dosing.
• Drug-Disease Interactions: Caution is required when prescribing Indacaterol to patients with underlying cardiovascular disease, seizure disorders, thyrotoxicosis, diabetes, or hypokalemia, as the drug may exacerbate these conditions.

Table 6: Clinically Significant Drug-Drug Interactions

Interacting Drug Class	Mechanism and Potential Effect	Clinical Recommendation	Source(s)
Other Sympathomimetic Agents (e.g., other LABAs, SABAs)	Additive adrenergic effects. Increased risk of cardiovascular adverse events.	Concomitant use of other LABAs is not recommended / contraindicated. Use other sympathomimetics with caution.
Beta-Adrenergic Blockers	Pharmacologic antagonism. Beta-blockers can block the bronchodilator effect of Indacaterol and induce severe bronchospasm.	Avoid combination. If necessary, use cardioselective beta-blockers with extreme caution.
Non-Potassium-Sparing Diuretics, Xanthine Derivatives, Corticosteroids	Can potentiate the hypokalemic effect of β2-agonists.	Use with caution and monitor serum potassium levels, especially in cases of hypoxia.
MAO Inhibitors, Tricyclic Antidepressants, QTc-Prolonging Drugs	May potentiate the effect of Indacaterol on the cardiovascular system, increasing the risk of QTc interval prolongation and ventricular arrhythmias.	Use with extreme caution.
Strong CYP3A4 and/or P-gp Inhibitors (e.g., ketoconazole, ritonavir)	Inhibition of metabolism and transport can increase systemic exposure (AUC) of Indacaterol up to two-fold.	Use with caution. While clinical trials have not shown safety concerns at higher exposures, potential for increased systemic effects exists.

Dosage, Administration, and Special Populations

Dosing and Administration

The recommended dosage and administration of Indacaterol differ between regulatory jurisdictions, reflecting different interpretations of the risk-benefit profile at higher doses.

• Dosage Forms and Strengths: Indacaterol is formulated as a dry powder for inhalation contained within hard gelatin capsules. These capsules are not to be swallowed and are intended for use only with a specific dry powder inhaler device.
• In the United States, it was marketed as Arcapta Neohaler and was available as a 75 microgram (mcg) capsule.
• In the European Union, it is marketed as Onbrez Breezhaler and is available in 150 mcg and 300 mcg strength capsules.
• Recommended Dosage:
• US: The recommended dosage was one 75 mcg capsule inhaled orally once daily.
• EU: The standard recommended dose is the inhalation of one 150 mcg capsule once daily. For patients with severe COPD who may require additional symptomatic benefit, the dose may be increased to one 300 mcg capsule once daily.
• Administration Instructions: The medication should be administered at the same time each day to maintain consistent bronchodilation. The capsules must be kept in the original blister pack until immediately before use to protect them from moisture. The patient places a single capsule into the chamber of the provided inhaler (Neohaler or Breezhaler), pierces the capsule by pressing buttons on the device, and then inhales the powder deeply through the mouthpiece. After inhalation, it is recommended that patients rinse their mouth with water without swallowing to reduce the risk of oropharyngeal side effects. If a dose is missed, it should be taken as soon as remembered, but no more than one dose should be taken in any 24-hour period.

Use in Special Populations

The use of Indacaterol has been evaluated in various special populations, with specific recommendations provided.

• Geriatric Population (≥65 years): No dosage adjustment is necessary for elderly patients. Clinical trials included a substantial proportion of geriatric patients, and analyses have not demonstrated any age-specific problems that would limit its usefulness or require a different dosing strategy. Efficacy and safety have been shown to be comparable to those in the general adult population.
• Pediatric Population (<18 years): Indacaterol is not indicated for use in children and adolescents. Its safety and efficacy have not been established in this population.
• Renal Impairment: No dose adjustment is required for patients with mild to moderate renal impairment. However, in patients with severe renal impairment or end-stage renal disease requiring dialysis, Indacaterol (particularly in combination products containing glycopyrronium, which is renally cleared) should be used with caution and only if the expected benefit outweighs the potential risk of increased systemic drug exposure.
• Hepatic Impairment: For patients with mild and moderate hepatic impairment, no dosage adjustment is required. There is no data available for the use of Indacaterol in patients with severe hepatic impairment; therefore, it should be used with caution in this group.
• Pregnancy and Lactation:
• Pregnancy: There are no adequate and well-controlled studies of Indacaterol in pregnant women. It is classified as US FDA Pregnancy Category C and Australian TGA Pregnancy Category B3. Animal reproduction studies did not show teratogenic effects at clinically relevant exposures but did show some evidence of fetal damage at very high doses, possibly secondary to maternal toxicity. As a beta-agonist, it has the potential to interfere with uterine contractility during labor. Therefore, Indacaterol should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus.
• Lactation: It is unknown whether Indacaterol or its metabolites are excreted in human milk, although they have been detected in the milk of lactating rats. Because of the potential for adverse reactions in the nursing infant, a decision must be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the medication to the mother.

Regulatory and Market History

Development and Manufacturer

Indacaterol was developed by the global pharmaceutical company Novartis Pharmaceuticals Corporation. Throughout its development, it was known by the investigational drug code QAB149. The development program was designed to produce a novel, once-daily inhaled β2-agonist with a unique pharmacological profile combining rapid onset with a 24-hour duration of action, specifically for the maintenance treatment of COPD.

Regulatory Approvals

Indacaterol underwent regulatory review by major health authorities globally, resulting in different approved dosages in Europe and the United States.

• European Medicines Agency (EMA): The EMA granted marketing authorization for Indacaterol on November 30, 2009. It is marketed in the European Union under the brand name Onbrez Breezhaler. The approval was for two once-daily doses: 150 µg and 300 µg. The EMA's assessment concluded that the 300 µg dose could provide additional clinical benefit with regard to breathlessness, particularly for patients with more severe COPD.
• U.S. Food and Drug Administration (FDA): The FDA approved Indacaterol on July 1, 2011, under the brand name Arcapta Neohaler. The approval journey in the US was more complex. In October 2009, Novartis received a Complete Response Letter from the FDA, indicating that the agency could not approve the application in its present form. Following further review and a recommendation from its advisory committee in March 2011, the FDA approved only the lower 75 mcg once-daily dose. The agency's rationale, later published, was that while higher doses provided slightly more bronchodilation, this additional benefit did not outweigh potential safety risks, thus leading to a more conservative risk-benefit assessment than that of the EMA.

Market Status and Brand Names

The commercial trajectory of Indacaterol reflects the evolving treatment landscape for COPD.

• Brand Names: The primary brand names for Indacaterol monotherapy are Onbrez Breezhaler (in Europe and other regions) and Arcapta Neohaler (in the US).
• Combination Products: Indacaterol has become the foundation for Novartis's portfolio of COPD combination therapies. Key combination products include:
• Utibron Neohaler / Ultibro Breezhaler: A dual LAMA/LABA combination with glycopyrronium.
• Enerzair Breezhaler / Zimbus Breezhaler: A triple LAMA/LABA/ICS therapy combining Indacaterol with glycopyrronium and mometasone furoate.
• Market Evolution and Discontinuation: The strategic focus of COPD treatment has shifted from monotherapy towards dual and triple combination therapies for many symptomatic patients, as reflected in global treatment guidelines. This shift has had a direct impact on the market status of Indacaterol monotherapy. In the US, Novartis has discontinued the marketing of Arcapta Neohaler. This move is best understood not as a failure of the drug, but as a strategic commercial decision to prioritize the more advanced and clinically comprehensive combination products. The value of Indacaterol as a molecule has transitioned from being a standalone product to being a critical platform component in the next generation of respiratory therapies. This is further evidenced by licensing deals, such as Novartis licensing the U.S. commercial rights for its Indacaterol-containing combination products to Sunovion Pharmaceuticals, indicating a focus on portfolio management and strategic partnerships.

This history illustrates a key dynamic in pharmaceutical development, where the interplay between clinical data (efficacy and safety), differing regulatory interpretations of risk-benefit, and evolving standards of care ultimately shapes a drug's life cycle and commercial strategy.

Expert Synthesis and Concluding Remarks

Indacaterol represents a significant and distinct milestone in the pharmacological management of Chronic Obstructive Pulmonary Disease. It is appropriately characterized as a landmark ultra-long-acting β2-agonist, distinguished by a unique pharmacodynamic profile that successfully combines two highly desirable therapeutic properties: a rapid onset of action, comparable to short-acting agents, and a sustained 24-hour duration of bronchodilation. This dual-action capability, which is a direct result of its molecular structure—combining high intrinsic efficacy for rapid receptor activation with high lipophilicity for prolonged retention in airway membrane lipid rafts—set a new benchmark for LABA therapy.

The clinical value of Indacaterol is substantiated by a robust and extensive development program. The evidence consistently demonstrates its ability to provide statistically significant and, more importantly, clinically meaningful improvements in lung function, dyspnea, and health-related quality of life for patients with moderate to severe COPD. Its superiority over older, twice-daily LABAs like salmeterol and formoterol is well-documented, and the convenience of its once-daily dosing regimen offers a tangible advantage for improving patient adherence to long-term maintenance therapy.

While Indacaterol is an effective monotherapy, its position within the therapeutic armamentarium has evolved in parallel with advancements in COPD treatment strategies. Current global guidelines increasingly advocate for the early use of dual-bronchodilator (LAMA/LABA) therapy for symptomatic patients to maximize bronchodilation and improve outcomes. Consequently, the primary clinical and commercial importance of Indacaterol today lies in its role as the foundational LABA component in highly effective, once-daily single-inhaler combination products. Its history exemplifies the transition of an innovative molecule from a standalone agent to a platform technology for next-generation therapies.

The risk-benefit profile of Indacaterol is well-characterized and considered acceptable for its indicated use. Prescribers must, however, remain vigilant regarding the class-wide risks associated with LABAs, including the contraindication for asthma monotherapy as highlighted in the FDA's Boxed Warning, and the potential for cardiovascular effects, particularly in patients with underlying comorbidities. The divergent dosing approvals between the United States and European regulatory agencies underscore the nuanced and sometimes subjective nature of risk-benefit assessment, but do not detract from the drug's established efficacy.

Looking forward, the legacy of Indacaterol will be defined by its role within these combination therapies. Real-world evidence and further head-to-head trials comparing different LAMA/LABA and triple therapy combinations will be crucial for refining personalized treatment algorithms for the heterogeneous COPD population.

In conclusion, Indacaterol was a pivotal innovation that redefined the expectations for a LABA in COPD management. While its application as a monotherapy has become more niche in certain markets, it remains a vital and highly effective component of modern, guideline-recommended combination therapies, continuing to provide significant and sustained clinical benefit to millions of patients worldwide.

Works cited

1. Indacaterol: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 28, 2025, https://go.drugbank.com/drugs/DB05039
2. Arcapta Neohaler (Indacaterol Inhalation Powder): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed July 28, 2025, https://www.rxlist.com/arcapta-neohaler-drug.htm
3. Indacaterol: a comprehensive review - PMC, accessed July 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3728154/
4. The role of indacaterol for chronic obstructive pulmonary disease (COPD) - Cazzola, accessed July 28, 2025, https://jtd.amegroups.org/article/view/1442/html
5. Once-daily indacaterol versus twice-daily salmeterol for COPD: a ..., accessed July 28, 2025, https://publications.ersnet.org/content/erj/37/2/273
6. Indacaterol for Chronic Obstructive Pulmonary Disease: Systematic Review and Meta-Analysis | PLOS One - Research journals, accessed July 28, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0070784
7. Comparative efficacy of long-acting beta2-agonists as monotherapy ..., accessed July 28, 2025, https://www.dovepress.com/comparative-efficacy-of-long-acting-beta2-agonists-as-monotherapy-for--peer-reviewed-fulltext-article-COPD
8. Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis - PubMed, accessed July 28, 2025, https://pubmed.ncbi.nlm.nih.gov/28176892/
9. Onbrez Breezhaler, INN-indacaterol, accessed July 28, 2025, https://ec.europa.eu/health/documents/community-register/2009/2009113069149/anx_69149_en.pdf
10. Reference ID: 4046214 This label may not be the latest approved by FDA. For current labeling information, please visit https:// - accessdata.fda.gov, accessed July 28, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207930s002lbl.pdf
11. Indacaterol acetate + Glycopyrronium bromide + Mometasone furoate - FDA Verification Portal, accessed July 28, 2025, https://verification.fda.gov.ph/files/DR-XY48483_PI_01.pdf
12. Indacaterol | C24H28N2O3 | CID 6918554 - PubChem, accessed July 28, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Indacaterol
13. Indacaterol: Indications, Side Effects, Warnings - Drugs.com, accessed July 28, 2025, https://www.drugs.com/cdi/indacaterol.html
14. Utibron Neohaler (glycopyrrolate and indacaterol) FDA Approval History - Drugs.com, accessed July 28, 2025, https://www.drugs.com/history/utibron-neohaler.html
15. Placing Novel, Fixed-Dose Dual Bronchodilators within the nice Guidelines for Chronic Obstructive Pulmonary Disease -Reflections on the Past, Present and Future - Peertechz Publications, accessed July 28, 2025, https://www.organscigroup.us/Pulmonology-Respiratory-Care/APRC-1-101.php
16. pubchem.ncbi.nlm.nih.gov, accessed July 28, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Indacaterol#:~:text=Indacaterol%20is%20a%20monohydroxyquinoline%20that,of%20chronic%20obstructive%20pulmonary%20disease.
17. Indacaterol | CAS 312753-06-3 | Cayman Chemical | Biomol.com, accessed July 28, 2025, https://www.biomol.com/products/chemicals/biochemicals/indacaterol-cay20070-50
18. Indacaterol in chronic obstructive pulmonary disease: an update for clinicians - PMC, accessed July 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3513896/
19. CHEBI:68575 - indacaterol - EMBL-EBI, accessed July 28, 2025, https://www.ebi.ac.uk/chebi/chebiOntology.do?chebiId=CHEBI:68575
20. File:Indacaterol structure.svg - Wikipedia, accessed July 28, 2025, https://en.m.wikipedia.org/wiki/File:Indacaterol_structure.svg
21. Indacaterol maleate | CAS#753498-25-8 | 312753-06-3 | g beta-adrenoceptor agonist, accessed July 28, 2025, https://www.medkoo.com/products/7255
22. Indacaterol (QAB149, CAS Number: 312753-06-3) | Cayman Chemical, accessed July 28, 2025, https://www.caymanchem.com/product/20070/indacaterol
23. Indacaterol Maleate | C28H32N2O7 | CID 9827599 - PubChem, accessed July 28, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Indacaterol-Maleate
24. CAS No : 312753-06-3 | Product Name : Indacaterol - API - Pharmaffiliates, accessed July 28, 2025, https://www.pharmaffiliates.com/en/312753-06-3-indacaterol-api-pa091450000.html
25. Indacaterol | CAS NO.:312753-06-3 - GlpBio, accessed July 28, 2025, https://www.glpbio.com/sp/indacaterol.html
26. 312753-06-3 Indacaterol AKSci W9904, accessed July 28, 2025, https://aksci.com/item_detail.php?cat=W9904
27. ARCAPTA NEOHALER® (indacaterol inhalation powder) - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed July 28, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022383s007lbl.pdf
28. Indacaterol Oral Inhalation: MedlinePlus Drug Information, accessed July 28, 2025, https://medlineplus.gov/druginfo/meds/a612014.html
29. Arcapta Neohaler™ Generic Name: Indacaterol Manufacturer¹,²: Novartis Drug Class¹,²,³, accessed July 28, 2025, https://pharmacy.hsc.wvu.edu/media/1132/arcapta-indacaterol.pdf
30. 022383Orig1s000 - accessdata.fda.gov, accessed July 28, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf
31. Indacaterol Completed Phase 4 Trials for Chronic Obstructive Pulmonary Disease (COPD) Treatment | DrugBank Online, accessed July 28, 2025, https://go.drugbank.com/drugs/DB05039/clinical_trials?conditions=DBCOND0031289&phase=4&purpose=treatment&status=completed
32. Indacaterol Completed Phase 2 Trials for Chronic Obstructive Pulmonary Disease (COPD) Supportive Care | DrugBank Online, accessed July 28, 2025, https://go.drugbank.com/drugs/DB05039/clinical_trials?conditions=DBCOND0031289&phase=2&purpose=supportive_care&status=completed
33. Indacaterol Completed Phase 3 Trials for Chronic Obstructive Pulmonary Disease (COPD) Treatment | DrugBank Online, accessed July 28, 2025, https://go.drugbank.com/drugs/DB05039/clinical_trials?conditions=DBCOND0031289&phase=3&purpose=treatment&status=completed
34. Indacaterol Completed Phase 2 Trials for Chronic Obstructive Pulmonary Disease (COPD) Treatment | DrugBank Online, accessed July 28, 2025, https://go.drugbank.com/drugs/DB05039/clinical_trials?conditions=DBCOND0031289&phase=2&purpose=treatment&status=completed
35. Systematic review comparing LABA, olodaterol, and indacaterol: limitations - PMC, accessed July 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4266268/
36. Onbrez Breezhaler | European Medicines Agency (EMA), accessed July 28, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/onbrez-breezhaler
37. Indacaterol/glycopyrronium bromide - Wikipedia, accessed July 28, 2025, https://en.wikipedia.org/wiki/Indacaterol/glycopyrronium_bromide
38. Indacaterol/glycopyrronium bromide/mometasone - Wikipedia, accessed July 28, 2025, https://en.wikipedia.org/wiki/Indacaterol/glycopyrronium_bromide/mometasone
39. Full article: Overuse of long-acting β2-agonist/inhaled corticosteroids in patients with chronic obstructive pulmonary disease: time to rethink prescribing patterns, accessed July 28, 2025, https://www.tandfonline.com/doi/full/10.1080/00325481.2023.2284650
40. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents - PubMed Central, accessed July 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2991288/
41. Comparative efficacy of long-acting beta2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis, accessed July 28, 2025, https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-of-long-acting-beta2-agonists-as-monotherapy-for-chronic-obstructive-pulmonary-disease--a-network-meta-analysis/
42. Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis - PMC - PubMed Central, accessed July 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5261557/
43. Indacaterol maleate + Glycopyrronium bromide - Ultibro - FDA Verification Portal, accessed July 28, 2025, https://verification.fda.gov.ph/files/DR-XY43865_PI_01.pdf
44. Ultibro Breezhaler, INN-indacaterol/glycopyrronium - Novartis, accessed July 28, 2025, https://www.novartis.com/sg-en/sites/novartis_sg/files/Ultibro%20Breezhaler%20PI%20June2020.SIN_App31082020.pdf
45. Onbrez Breezhaler 150microgram inhalation powder capsules with device (Novartis Pharmaceuticals UK Ltd) 30 capsule 3 x 10 capsules - RightBreathe, accessed July 28, 2025, https://www.rightbreathe.com/medicines/onbrez-breezhaler-150microgram-inhalation-powder-capsules-with-device-novartis-pharmaceuticals-uk-ltd-30-capsule-3-x-10-capsules/
46. Indacaterol Advanced Patient Information - Drugs.com, accessed July 28, 2025, https://www.drugs.com/cons/indacaterol.html
47. Indacaterol: Uses, Side Effects and Medicines | Apollo Pharmacy, accessed July 28, 2025, https://www.apollopharmacy.in/salt/Indacaterol
48. Indacaterol : Indications, Uses, Dosage, Drugs Interactions, Side effects - Medical Dialogues, accessed July 28, 2025, https://medicaldialogues.in/generics/indacaterol-2721603
49. Indacaterol (inhalation route) - Side effects & dosage - Mayo Clinic, accessed July 28, 2025, https://www.mayoclinic.org/drugs-supplements/indacaterol-inhalation-route/description/drg-20075006
50. Indacaterol inhalation powder - Cleveland Clinic, accessed July 28, 2025, https://my.clevelandclinic.org/health/drugs/19698-indacaterol-inhalation-powder
51. Indacaterol Interactions Checker - Drugs.com, accessed July 28, 2025, https://www.drugs.com/drug-interactions/indacaterol.html
52. Indacaterol Maleate+glycopyrronium Bromide: Uses, Side Effects and Medicines, accessed July 28, 2025, https://www.apollopharmacy.in/salt/Indacaterol%20Maleate+glycopyrronium%20Bromide
53. Study Details | Evaluation of Pharmacokinetic Interaction of Indacaterol With Ketoconazole in Healthy Adult Subjects | ClinicalTrials.gov, accessed July 28, 2025, https://clinicaltrials.gov/study/NCT00410501
54. Indacaterol Alternatives Compared - Drugs.com, accessed July 28, 2025, https://www.drugs.com/compare/indacaterol
55. Arcapta Neohaler (indacaterol inhaled) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed July 28, 2025, https://reference.medscape.com/drug/arcapta-neohaler-indacaterol-inhaled-999669
56. indacaterol (inhalation) - Watertown Internists, accessed July 28, 2025, https://www.watertowninternists.com/PatientPortal/MyPractice.aspx?UAID={3C7DCB0A-303F-408F-B4FE-7BE705956F23}&ID=HW5d07651a1&Title=indacaterol-(inhalation)
57. Indacaterol Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed July 28, 2025, https://www.drugs.com/dosage/indacaterol.html
58. Indacaterol and glycopyrrolate (inhalation route) - Side effects & dosage - Mayo Clinic, accessed July 28, 2025, https://www.mayoclinic.org/drugs-supplements/indacaterol-and-glycopyrrolate-inhalation-route/description/drg-20165147
59. Enerzair Breezhaler, INN-indacaterol/glycopyrronium/mometasone furoate - EMA, accessed July 28, 2025, https://www.ema.europa.eu/en/documents/product-information/enerzair-breezhaler-epar-product-information_en.pdf
60. Glycopyrrolate / indacaterol (Utibron Neohaler) Use During Pregnancy - Drugs.com, accessed July 28, 2025, https://www.drugs.com/pregnancy/glycopyrrolate-indacaterol.html
61. Indacaterol (Arcapta) Use During Pregnancy - Drugs.com, accessed July 28, 2025, https://www.drugs.com/pregnancy/indacaterol.html
62. Indacaterol - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf, accessed July 28, 2025, https://www.ncbi.nlm.nih.gov/books/NBK501916/
63. Indacaterol - Wikipedia, accessed July 28, 2025, https://en.wikipedia.org/wiki/Indacaterol
64. Arcapta (indacaterol) FDA Approval History - Drugs.com, accessed July 28, 2025, https://www.drugs.com/history/arcapta.html
65. Novartis Pharmaceuticals collaborates with Qualcomm in digital innovation with the Breezhaler(TM) inhaler device to treat COPD, accessed July 28, 2025, https://www.novartis.com/news/media-releases/novartis-pharmaceuticals-collaborates-qualcomm-digital-innovation-breezhalertm-inhaler-device-treat-copd
66. Novartis receives FDA approval for Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease, accessed July 28, 2025, https://www.novartis.com/us-en/news/media-releases/novartis-receives-fda-approval-arcaptatm-neohalertm-novel-once-daily-bronchodilator-chronic-obstructive-pulmonary-disease
67. Novartis launches the Arcapta Neohaler in the US - OINDPnews, accessed July 28, 2025, https://www.oindpnews.com/2012/03/novartis-launches-the-arcapta-neohaler-in-the-us/
68. indacaterol - PharmGKB, accessed July 28, 2025, https://www.pharmgkb.org/chemical/PA165958348
69. go.drugbank.com, accessed July 28, 2025, https://go.drugbank.com/drugs/DB05039#:~:text=It%20is%20marketed%20in%20Europe,as%20its%20maleate%20salt%20form.